Key result
Aggressive chemoprophylaxis carries a 5% to 7% risk of major bleeding without reducing fatal pulmonary embolism compared to safer agents like aspirin.
Why the study?
Do aggressive chemoprophylactic agents increase bleeding risks without significantly reducing fatal pulmonary embolism compared to less aggressive agents in patients following primary total knee arthroplasty?
Do aggressive chemoprophylactic agents increase bleeding risks without significantly reducing fatal pulmonary embolism compared to less aggressive agents in patients following primary total knee arthroplasty?
Answers are grounded in this paper and cite their sources.
Aggressive chemoprophylaxis after total knee arthroplasty may carry high bleeding risks without significantly lowering the already low rate of fatal pulmonary embolism compared to aspirin.
To The Editor: After reading the article Prevention of Venous Thromboembolic Disease Following Primary Total Knee Arthroplasty. A Randomized, Multicenter, Open-Label, Parallel-Group Comparison of Enoxaparin and Warfarin (2001;83:900-6), by Fitzgerald et al., I was impressed by the 5% to 7% rate of major hemorrhagic complications, including a death from retroperitoneal hemorrhage. I am also concerned about the readiness of many in the orthopaedic community to disregard the data that have been reported on less aggressive and safer agents such as aspirin. Despite articles1-4 that clearly show no significant difference in the incidence of fatal pulmonary embolism (i.e., 0.1% to 0.2%) with or without aggressive chemoprophylactic agents, the use of some anticoagulant agents associated with risks of bleeding that are as high as 7% are being incorporated into the standard of care in our country. The cost of these agents and the subsequent medical costs for dealing with their potential complications should also be considered. …
No takes yet. Share an insight, caveat, or question.
Paul A. Lotke (2002) conducted a letter in Venous thromboembolic disease following primary total knee arthroplasty. Aggressive chemoprophylactic agents (e.g., enoxaparin, warfarin) vs. Less aggressive agents (e.g., aspirin) was evaluated. Aggressive chemoprophylaxis carries a 5% to 7% risk of major bleeding without reducing fatal pulmonary embolism compared to safer agents like aspirin.
Synapse has enriched 10 related papers. Consider them for comparative context: